OPEN Act
Latest action · Mar 3, 2017 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedFeb 27, 2017
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 or the OPEN Act
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Department of Health and Human Services (HHS) to extend by six months the exclusivity period for a drug or biological product approved by the Food and Drug Administration (FDA) when the product is additionally approved to prevent, diagnose, or treat a new indication that is a rare disease or condition (also known as an orphan disease).
HHS may revoke an extension if the application submitted to the FDA for the new indication contained an untrue material statement.
HHS must notify the public of products that receive this extension and patents related to those products.
Products may receive only one extension under this bill. Extensions under this bill are in addition to other extensions.
The bill applies only to products approved after enactment of this bill for a new indication that is a rare disease or condition.Cosponsors 43
Members who signed on, in the order they did. Signatures ran from Feb 27, 2017 to Oct 16, 2018; 2 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NC | G. K. Butterfield | Original | Feb 27, 2017 |
| R-TX | Michael T. McCaul | Original | Feb 27, 2017 |
| D-FL | Darren Soto | Mar 1, 2017 | |
| R-NJ | Leonard Lance | Mar 1, 2017 | |
| R-NJ | Rodney P. Frelinghuysen | Mar 1, 2017 | |
| D-CA | Anna G. Eshoo | Mar 8, 2017 | |
| R-NY | Daniel M. Donovan, Jr. | Mar 8, 2017 | |
| R-PA | Tim Murphy | Mar 8, 2017 | |
| D-NJ | Donald Norcross | Mar 16, 2017 | |
| R-OK | Markwayne Mullin | Mar 16, 2017 | |
| D-CA | Jared Huffman | Mar 24, 2017 | |
| R-NE | Jeff Fortenberry | Mar 24, 2017 | |
| R-FL | Daniel Webster | Apr 3, 2017 | |
| R-NE | Don Bacon | Apr 3, 2017 | |
| R-MS | Steven M. Palazzo | May 22, 2017 | |
| R-FL | Francis Rooney | Jun 12, 2017 | |
| D-CA | Zoe Lofgren | Jun 23, 2017 | |
| R-WA | Cathy McMorris Rodgers | Jun 27, 2017 | |
| D-NJ | Albio Sires | Jun 28, 2017 | |
| D-CA | Eric Swalwell | Jun 28, 2017 | |
| R-MI | Fred Upton | Jul 11, 2017 | |
| R-TX | Pete Olson | Jul 12, 2017 | |
| R-MO | Billy Long | Jul 28, 2017 | |
| D-NH | Carol Shea-Porter | Sep 5, 2017 | |
| R-AL | Mo Brooks | Sep 5, 2017 | |
| R-OH | Steve Stivers | Sep 13, 2017 | |
| D-MO | Wm. Lacy Clay | Oct 11, 2017 | |
| D-FL | Alcee L. Hastings | Mar 5, 2018 | |
| R-VA | Barbara Comstock | Mar 5, 2018 | |
| R-PA | Brian K. Fitzpatrick | Mar 5, 2018 | |
| R-NJ | Christopher H. Smith | Mar 5, 2018 | |
| D-NM | Michelle Lujan Grisham | Mar 6, 2018 | |
| R-IA | David Young | Apr 10, 2018 | |
| R-TX | John Abney Culberson | May 1, 2018 | |
| D-NY | Kathleen M. Rice | Jun 12, 2018 | |
| D-NJ | Bonnie Watson Coleman | Jun 19, 2018 | |
| D-IN | Peter J. Visclosky | Jul 17, 2018 | |
| R-WA | David G. Reichert | Jul 31, 2018 | |
| R-FL | Bill Posey | Aug 28, 2018 | |
| R-IN | Luke Messer | Aug 28, 2018 | |
| R-IL | Peter J. Roskam | Aug 31, 2018 | |
| R-TX | Ted Poe | Sep 4, 2018 | |
| D-NC | David E. Price | Oct 16, 2018 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Feb 27, 2017 |
| Health Subcommittee | Referred Mar 3, 2017 |
Actions 3
Everything that happened, newest first.
- Mar 3, 2017Referred to the Subcommittee on Health.
- Feb 27, 2017Introduced in House
- Feb 27, 2017Referred to the House Committee on Energy and Commerce.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 163, no. 34, February 27, 2017, page H1355.
Printed hearings 1
Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.
| Number | Hearing | Committee | Held |
|---|---|---|---|
| S. Hrg. 115-403 | THE 30TH ANNIVERSARY OF TRIBAL SELF-GOVERNANCE: SUCCESSES IN SELF- GOVERNANCE AND AN OUTLOOK FOR THE NEXT 30 YEARS49 pages | Indian Affairs Committee | Apr 18, 2018 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1509 | Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017 | Related bill | Jun 29, 2017 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act to authorize an extension of exclusivity periods for certain drugs that are approved for a new indication for a rare disease or condition, and for other purposes.
- Short Titles as Introduced
- OPEN Act
- Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Feb 27, 2017Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.